Recordati stock: Equita targets EUR 69.00 for Recordati stock? no

Published on 10/20/2026 at 16:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eight analysts set a EUR 60.10 average target on October 19, 2026. Recordati stock costs EUR 52.98 on October 20, 2026 at 4:38 p.m. CEST, up 0.06 percent versus Borsa Italiana close.

Analyst view and price

Equita set a EUR 69.00 target for Recordati on October 6, 2026.
Eight analysts had an average target of EUR 60.10 on October 19, 2026.
Recordati stock costs EUR 52.98 at Lang & Schwarz on October 20, 2026 at 4:38 p.m. CEST, up 0.06 percent versus the Borsa Italiana close of October 19, 2026.

Makroaufnahme verschiedener Pharma-Tabletten und Kapseln mit feiner Textur — Recordati S.p.A. (IT0003828271) stellt Tabletten und Kapseln her, hier als Makroaufnahme mit feinen Oberflächendetails gezeigt, Illustration mit AI erstellt.

Recordati stock is trading at EUR 52.98 at Lang & Schwarz on October 20, 2026 at 4:38 p.m. CEST, up 0.06 percent versus the Borsa Italiana close of October 19, 2026 at EUR 52.95. On October 6, 2026, Equita maintained a buy view and set a EUR 69.00 target, according to Il Sole 24 Ore.

Target gap remains substantial

The Equita target stands 30.24 percent above the Lang & Schwarz price. The same October 6 report cited Banca Akros with a EUR 65.00 target and Intermonte with a EUR 71.00 target, placing the three published targets between EUR 65.00 and EUR 71.00.

That spread matters because the stock is trading close to the EUR 53.00 offer level discussed in the takeover process. The analyst figures instead value Recordati on its standalone earnings potential, with the report highlighting Isturisa and the company's agreement with Moderna.

Stock sits near its yearly high

Recordati traded between EUR 44.48 and EUR 54.05 over the 52 weeks to September 29, 2026. At EUR 52.98, the stock is 1.98 percent below that high and 19.11 percent above the low. The dated market value was EUR 10.87 billion on September 29, 2026.

The price position leaves limited room between the current quote and the reported yearly high. It also places the share 13.44 percent below the EUR 60.10 average target for eight analysts reported by Marketscreener on October 19, 2026.

Next results date is November 10

Recordati's next scheduled reporting event is the third-quarter 2026 earnings release on November 10, 2026, followed by an earnings presentation on November 11, 2026, according to Marketscreener. The investor-relations page identifies Recordati as a pharmaceutical company with more than 4,700 employees and operations in around 150 countries, while its 2026 calendar lists first-half results on July 29, 2026, according to Recordati.

Price and investor perspective

The reported analyst targets provide the clearest valuation counterpoint to a share price constrained near EUR 53.00. The November 10 results date is the next scheduled point at which operating performance can be measured against those expectations.

Recordati was trading at EUR 52.98 at Lang & Schwarz on October 20, 2026 at 4:38 p.m. CEST, up 0.06 percent versus the Borsa Italiana close of October 19, 2026 at EUR 52.95. The further course of trading is shown by the continuously updated real-time quote of Recordati stock.